Sol Gel Technologies Ltd
SLGL4.804USD
+0.383+8.68%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
133.82MCap. mercado
PérdidaP/E TTM
Más Datos de Sol Gel Technologies Ltd Compañía
Sol-Gel Technologies Ltd is a clinical-stage dermatology company. The Company is focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Company’s offers a range of products twins, sirs-t, and vered. The Company is designed its proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin.
Información de la empresa
Código de la empresaSLGL
Nombre de la empresaSol Gel Technologies Ltd
Fecha de salida a bolsaFeb 01, 2018
Fundada en1997
Director ejecutivo- -
Número de empleados34
Tipo de seguridadOrdinary Share
Fin del año fiscalFeb 01
DirecciónGolda Meir 7
CiudadNESS-ZIONA
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísIsrael
Código postal- -
Teléfono97289313433
Sitio Webhttp://www.sol-gel.com
Código de la empresaSLGL
Fecha de salida a bolsaFeb 01, 2018
Fundada en1997
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Moshe (Mori) Arkin
Mr. Moshe (Mori) Arkin
Executive Chairman of the Board
Executive Chairman of the Board
38.13K
+343.42%
Dr. Karine Neimann, Ph.D.
Dr. Karine Neimann, Ph.D.
Vice President - Projects and Planning, Chief Chemist
Vice President - Projects and Planning, Chief Chemist
--
--
Ms. Yaffa Krindel
Ms. Yaffa Krindel
Independent Director
Independent Director
--
--
Dr. Shmuel (Muli) Ben Zvi, Ph.D.
Dr. Shmuel (Muli) Ben Zvi, Ph.D.
Independent Director
Independent Director
--
--
Mr. Ran Gottfried
Mr. Ran Gottfried
Lead Independent Director
Lead Independent Director
--
--
Mr. Eyal Ben-Or
Mr. Eyal Ben-Or
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Hani Lerman
Ms. Hani Lerman
Director
Director
--
--
Dr. Ofra Levy-Hacham, Ph.D.
Dr. Ofra Levy-Hacham, Ph.D.
Vice President - Clinical and Regulatory Affairs
Vice President - Clinical and Regulatory Affairs
--
--
Dr. Ofer Toledano, Ph.D.
Dr. Ofer Toledano, Ph.D.
Vice President - Research and Development
Vice President - Research and Development
--
--
Mr. Nissim Bilman
Mr. Nissim Bilman
Vice President - Quality
Vice President - Quality
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Moshe (Mori) Arkin
Mr. Moshe (Mori) Arkin
Executive Chairman of the Board
Executive Chairman of the Board
38.13K
+343.42%
Dr. Karine Neimann, Ph.D.
Dr. Karine Neimann, Ph.D.
Vice President - Projects and Planning, Chief Chemist
Vice President - Projects and Planning, Chief Chemist
--
--
Ms. Yaffa Krindel
Ms. Yaffa Krindel
Independent Director
Independent Director
--
--
Dr. Shmuel (Muli) Ben Zvi, Ph.D.
Dr. Shmuel (Muli) Ben Zvi, Ph.D.
Independent Director
Independent Director
--
--
Mr. Ran Gottfried
Mr. Ran Gottfried
Lead Independent Director
Lead Independent Director
--
--
Mr. Eyal Ben-Or
Mr. Eyal Ben-Or
Chief Financial Officer
Chief Financial Officer
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Accionista
Hora de actualización: dom., 4 de may
Hora de actualización: dom., 4 de may
Estadísticas de accionistas
Tipo
Estadísticas de accionistas
Accionista
Proporción
M.Arkin Dermatology, Ltd.
64.86%
Phoenix Investment and Finances Ltd
8.87%
Migdal Insurance and Financial Holdings Ltd
4.41%
Harel Insurance Investments and Financial Services Ltd
3.30%
Arkin (Moshe)
1.37%
Other
17.19%
Estadísticas de accionistas
Accionista
Proporción
M.Arkin Dermatology, Ltd.
64.86%
Phoenix Investment and Finances Ltd
8.87%
Migdal Insurance and Financial Holdings Ltd
4.41%
Harel Insurance Investments and Financial Services Ltd
3.30%
Arkin (Moshe)
1.37%
Other
17.19%
Tipo
Accionista
Proporción
Corporation
64.86%
Investment Advisor
13.44%
Insurance Company
4.68%
Individual Investor
1.37%
Research Firm
0.60%
Investment Advisor/Hedge Fund
0.05%
Other
15.00%
Participación institucional
Hora de actualización: mar., 4 de mar
Hora de actualización: mar., 4 de mar
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q1
35
2.45M
67.44%
+70.65K
2024Q4
35
23.50M
84.37%
-314.30K
2024Q3
34
23.55M
84.52%
-115.49K
2024Q2
31
25.52M
91.61%
+1.51M
2024Q1
30
23.87M
85.67%
+1.61M
2023Q4
31
22.12M
83.66%
-222.95K
2023Q3
30
22.20M
83.99%
-4.35K
2023Q2
29
22.04M
83.43%
-335.52K
2023Q1
32
22.23M
86.47%
+2.20M
2022Q4
34
20.25M
87.57%
+14.11M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
M.Arkin Dermatology, Ltd.
18.07M
64.86%
+2.00M
+12.45%
Apr 03, 2024
Phoenix Investment and Finances Ltd
2.47M
8.87%
--
--
Dec 31, 2024
Migdal Insurance and Financial Holdings Ltd
1.23M
4.41%
--
--
Dec 31, 2024
Harel Insurance Investments and Financial Services Ltd
920.33K
3.3%
--
--
Dec 31, 2024
Arkin (Moshe)
86.00K
0.31%
--
--
Apr 03, 2024
Yelin Lapidot Provident Funds Management Ltd
227.08K
0.82%
-2.10K
-0.92%
Dec 31, 2024
Morgan Stanley & Co. LLC
88.24K
0.32%
+54.88K
+164.51%
Dec 31, 2024
Menora Mivtachim Insurance Ltd.
76.11K
0.27%
--
--
Dec 31, 2024
BNP Paribas Securities Corp. North America
39.50K
0.14%
+1.80K
+4.77%
Dec 31, 2024
Ver más
ETFs relacionados
Hora de actualización: hace 7 horas
Hora de actualización: hace 7 horas
Nombre
Proporción
Invesco Raymond James SB-1 Equity ETF
0%
Invesco Raymond James SB-1 Equity ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos